Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.82 |
| ▸ | GSK3B | P49841 | 1/20 | 0.73 |
| ▸ | SYK | P43405 | 2/20 | 0.70 |
| ▸ | CDK2 | P24941 | 4/20 | 0.68 |
| ▸ | CDK1 | P06493 | 3/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.62 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 7/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459525 | 0.91 | IGF1R (1.00) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL3275303 | 0.87 | SYK (0.92) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL6826392 | 0.87 | AURKA (0.67) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL5261726 | 0.87 | IGF1R (0.85) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL3276895 | 0.85 | IGF1R (0.82) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL5262378 | 0.85 | GSK3B (1.00) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL3270189 | 0.82 | IGF1R (0.72) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL656905 | 0.82 | SYK (1.00) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL6643538 | 0.82 | IGF1R (0.63) | IGF1RGSK3BSYKCDK2CDK1 | |
| SCHEMBL2936141 | 0.82 | IGF1R (0.76) | IGF1RGSK3BSYKCDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278735-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| US-7067522-B2 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| CN-1220684-C | 2,4,Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2005-09-28 | — | — | CN | disclosed |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB | 2005-04-28 | — | — | US | disclosed |
| US-6838464-B2 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| EP-1140860-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | disclosed |
| US-6593326-B1 | Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | disclosed |
| CN-1416423-A | 2,4,Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-05-07 | — | — | CN | disclosed |
| EP-1278735-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| EP-1140860-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001064656-A1 | 2,4,DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000039101-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | IGF1R 967/4885GSK3B 572/4885SYK 116/4885 |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | CDK2, CDK4, CCNI | IGF1R 1072/4885GSK3B 568/4885SYK 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.